160 related articles for article (PubMed ID: 37587323)
41. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
42. Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C.
Ahn SH; Choe WH; Kim YJ; Heo J; Latarska-Smuga D; Kang J; Paik SW
Gut Liver; 2020 May; 14(3):368-376. PubMed ID: 31533395
[TBL] [Abstract][Full Text] [Related]
43. Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF; Lapidus N; Dorival C; Diallo A; Amri I; Fontaine H; Pol S; Carrat F;
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):797-805. PubMed ID: 29749668
[TBL] [Abstract][Full Text] [Related]
44. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
45. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
Gambato M; Canini L; Lens S; Graw F; Perpiñan E; Londoño MC; Uprichard SL; Mariño Z; Reverter E; Bartres C; González P; Pla A; Costa J; Burra P; Cotler SJ; Forns X; Dahari H
Liver Int; 2019 May; 39(5):826-834. PubMed ID: 30499631
[TBL] [Abstract][Full Text] [Related]
46. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
47. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
48. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.
Barré T; Carrat F; Ramier C; Fontaine H; Di Beo V; Bureau M; Dorival C; Larrey D; Delarocque-Astagneau E; Mathurin P; Marcellin F; Petrov-Sanchez V; Cagnot C; Carrieri P; Pol S; Protopopescu C;
J Cannabis Res; 2022 Jun; 4(1):31. PubMed ID: 35690798
[TBL] [Abstract][Full Text] [Related]
49. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
[TBL] [Abstract][Full Text] [Related]
50. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
[TBL] [Abstract][Full Text] [Related]
51. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
52. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.
Toyoda H; Kikuchi K
Ther Apher Dial; 2023 Oct; 27(5):831-838. PubMed ID: 37217295
[TBL] [Abstract][Full Text] [Related]
53. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study.
Kaur H; Dhiman RK; Kulkarni AV; Premkumar M; Singh V; Duseja AK; Grover S; Grover GS; Roy A; Verma N; De A; Taneja S; Mehtani R; Mishra S; Kaur H
J Viral Hepat; 2022 May; 29(5):395-406. PubMed ID: 35266624
[TBL] [Abstract][Full Text] [Related]
54. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
Grotzinger KM; Younossi ZM; Giannini EG; Chen PJ; Rendas-Baum R; Theodore D
Health Qual Life Outcomes; 2016 Mar; 14():49. PubMed ID: 27004952
[TBL] [Abstract][Full Text] [Related]
55. Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME;
PLoS One; 2016; 11(6):e0150655. PubMed ID: 27355323
[TBL] [Abstract][Full Text] [Related]
56. Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.
Lam L; Fontaine H; Lapidus N; Bellet J; Lusivika-Nzinga C; Nicol J; Dorival C; Cagnot C; Hejblum G; Pol S; Bourlière M; Carrat F;
J Viral Hepat; 2023 Mar; 30(3):232-241. PubMed ID: 36529681
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
58. Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world.
Donaldson SR; Radley A; Dillon JF
Subst Abuse Treat Prev Policy; 2022 Jun; 17(1):45. PubMed ID: 35676732
[TBL] [Abstract][Full Text] [Related]
59. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study.
Yeung MW; Young J; Moodie E; Rollet-Kurhajec KC; Schwartzman K; Greenaway C; Cooper C; Cox J; Gill J; Hull M; Walmsley S; Klein MB
HIV Clin Trials; 2015; 16(3):100-10. PubMed ID: 25972048
[TBL] [Abstract][Full Text] [Related]
60. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.
Coyer L; Njoya O; Njouom R; Mossus T; Kowo MP; Essomba F; Boers A; Coutinho R; Ondoa P;
Trop Med Int Health; 2020 Sep; 25(9):1098-1109. PubMed ID: 32502290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
